The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)*
Abstract
OBJECTIVE: The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute Physiology and Chronic Health Evaluation II score, MOD score, and d-dimer. DESIGN: Randomized, double-masked, placebo-controlled, single-center clinical trial, testing low dose continuous infusion of unfractioned heparin (UFH) as complementary treatment for sepsis. SETTING: Five hundred fifty bed University Hospital and referral center in Medellín, Columbia. PATIENTS: Three hundred nineteen patients admitted at the emergency room with signs indicative of sepsis. INTERVENTIONS: Patients were randomly assigned to receive placebo or UFH (500 units/hour for 7 days). MEASUREMENTS AND MAIN RESULTS: The median length of stay in patients discharged alive in the placebo group was 12.5 days (interquartile range = 8-20), and 12 days (interquartile range = 8-19.5) in the heparin group (p = 0.976). The MOD score improved equally in the two treatments arms with an average decline of 0.13 and 0.11 per day for the placebo and heparin groups (p = 0.240), respectively. The overall 28-day mortality was 16% in the placebo group and 14% in the heparin group (p = 0.652). Subgroup analyses did not show any statistically significant reduction in 28-day mortality with UFH. There was only one serious adverse event on a patient who received heparin but it was fully resolved without complications. CONCLUSIONS: Our findings suggested that UFH may be a feasible and safe intervention in sepsis. However, this study was not able to demonstrate a beneficial effect on the chosen primary outcomes or in the 28-day mortality rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Cited by
Sepsis: pathophysiology and clinical management
Gotts, J. E., & Matthay, M. A. (2016) · BMJ · doi:10.1136/bmj.i1585 · Cited by 1,243
Jackson, S. P., Darbousset, R., & Schoenwaelder, S. M. (2019) · Blood · doi:10.1182/blood-2018-11-882993 · Cited by 616
Disseminated intravascular coagulation
Gando, S., Levi, M., & Toh, C.-H. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.37 · Cited by 572
Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., & Remick, D. G. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130327 · Cited by 549
Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation
Iba, T., Levy, J. H., Warkentin, T. E., Thachil, J., van der Poll, T., & Levi, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14578 · Cited by 531
Metadata
- Authors
- Jaimes, F., De La Rosa, G., Morales, C., Fortich, F., Arango, C., Aguirre, D., & Muñoz, Á.
- Venue
- Critical Care Medicine
- Published
- 2009-04
- Volume
- 37
- Issue
- 4
- Pages
- 1185-1196
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2059426768
- Cited by
- 194
- References
- 1
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)*. https://app.cochat.ai/papers/10.1097/ccm.0b013e31819c06bc
- The paper
- Jaimes, F., De La Rosa, G., Morales, C., Fortich, F., Arango, C., Aguirre, D., & Muñoz, Á. (2009). Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e31819c06bc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.